Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297721 | 0.86 | NPC1 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3221579 | 0.85 | CA1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL20565891 | 0.85 | MAPT (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15391492 | 0.85 | NFE2L2 (0.43) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16954488 | 0.82 | LMNA (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16957045 | 0.82 | CA1 (0.38) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16954050 | 0.80 | TLR2 (0.43) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16950358 | 0.76 | CTSD (0.36) | CA1CA2CA7CA9CA12 | |
| SCHEMBL374648 | 0.75 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL18245688 | 0.75 | CA1 (0.50) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396313-A | Alkenyl borate, and preparation method and application thereof | 中山大学 | 2023-07-07 | — | — | CN | claimed |
| CN-103951685-A | New beta-diketone rare earth organic complex and its preparation method | UNIV HUIZHOU | 2014-07-30 | — | — | CN | claimed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | claimed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | claimed |
| CN-116396313-A | Alkenyl borate, and preparation method and application thereof | 中山大学 | 2023-07-07 | — | — | CN | disclosed |
| CN-106661031-B | Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it | 大鹏药品工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3103802-B1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-8507610-B2 | Modified polymer material modified by nitrile oxide, and production method thereof | TOYODA GOSEI CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2011139704-A2 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139704-A2 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | CA1 2565/4885CA2 2864/4885CA7 3167/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | CA1 1126/4885CA2 625/4885CA7 396/4885 |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | TCP1, CCT3, CCT2 | CA1 77/4885CA2 55/4885CA7 453/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | CA1 1126/4885CA2 625/4885CA7 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.